186 related articles for article (PubMed ID: 34059744)
21. Obesity, Aspirin, and Risk of Colorectal Cancer in Carriers of Hereditary Colorectal Cancer: A Prospective Investigation in the CAPP2 Study.
Movahedi M; Bishop DT; Macrae F; Mecklin JP; Moeslein G; Olschwang S; Eccles D; Evans DG; Maher ER; Bertario L; Bisgaard ML; Dunlop MG; Ho JW; Hodgson SV; Lindblom A; Lubinski J; Morrison PJ; Murday V; Ramesar RS; Side L; Scott RJ; Thomas HJ; Vasen HF; Burn J; Mathers JC
J Clin Oncol; 2015 Nov; 33(31):3591-7. PubMed ID: 26282643
[TBL] [Abstract][Full Text] [Related]
22. Prevalence of mutations in BRCA and MMR genes in patients affected with hereditary endometrial cancer.
Vietri MT; D'Elia G; Caliendo G; Casamassimi A; Federico A; Passariello L; Cioffi M; Molinari AM
Med Oncol; 2021 Jan; 38(2):13. PubMed ID: 33484353
[TBL] [Abstract][Full Text] [Related]
23. DNA repair gene polymorphisms and risk of early onset colorectal cancer in Lynch syndrome.
Reeves SG; Meldrum C; Groombridge C; Spigelman A; Suchy J; Kurzawski G; Lubinski J; Scott RJ
Cancer Epidemiol; 2012 Apr; 36(2):183-9. PubMed ID: 21974800
[TBL] [Abstract][Full Text] [Related]
24. Elucidating the molecular basis of MSH2-deficient tumors by combined germline and somatic analysis.
Vargas-Parra GM; González-Acosta M; Thompson BA; Gómez C; Fernández A; Dámaso E; Pons T; Morak M; Del Valle J; Iglesias S; Velasco À; Solanes A; Sanjuan X; Padilla N; de la Cruz X; Valencia A; Holinski-Feder E; Brunet J; Feliubadaló L; Lázaro C; Navarro M; Pineda M; Capellá G
Int J Cancer; 2017 Oct; 141(7):1365-1380. PubMed ID: 28577310
[TBL] [Abstract][Full Text] [Related]
25. Excess of extracolonic non-endometrial multiple primary cancers in MSH2 germline mutation carriers over MLH1.
Lin-Hurtubise KM; Yheulon CG; Gagliano RA; Lynch HT
J Surg Oncol; 2013 Dec; 108(7):433-7. PubMed ID: 24122742
[TBL] [Abstract][Full Text] [Related]
26. Germline mismatch repair gene variants analyzed by universal sequencing in Japanese cancer patients.
Kiyozumi Y; Matsubayashi H; Horiuchi Y; Higashigawa S; Oishi T; Abe M; Ohnami S; Urakami K; Nagashima T; Kusuhara M; Miyake H; Yamaguchi K
Cancer Med; 2019 Sep; 8(12):5534-5543. PubMed ID: 31386297
[TBL] [Abstract][Full Text] [Related]
27. Multigene Panel Testing Provides a New Perspective on Lynch Syndrome.
Espenschied CR; LaDuca H; Li S; McFarland R; Gau CL; Hampel H
J Clin Oncol; 2017 Aug; 35(22):2568-2575. PubMed ID: 28514183
[TBL] [Abstract][Full Text] [Related]
28. Screening for germline mutations of MLH1, MSH2, MSH6 and PMS2 genes in Slovenian colorectal cancer patients: implications for a population specific detection strategy of Lynch syndrome.
Berginc G; Bracko M; Ravnik-Glavac M; Glavac D
Fam Cancer; 2009; 8(4):421-9. PubMed ID: 19526325
[TBL] [Abstract][Full Text] [Related]
29. Impact of gene-specific germline pathogenic variants on presentation of endometrial cancer in Lynch syndrome.
Bogani G; Ricci MT; Vitellaro M; Ditto A; Chiappa V; Raspagliesi F
Int J Gynecol Cancer; 2019 May; 29(4):705-710. PubMed ID: 30772826
[TBL] [Abstract][Full Text] [Related]
30. SNP association study in PMS2-associated Lynch syndrome.
Ten Broeke SW; Elsayed FA; Pagan L; Olderode-Berends MJW; Garcia EG; Gille HJP; van Hest LP; Letteboer TGW; van der Kolk LE; Mensenkamp AR; van Os TA; Spruijt L; Redeker BJW; Suerink M; Vos YJ; Wagner A; Wijnen JT; Steyerberg EW; Tops CMJ; van Wezel T; Nielsen M
Fam Cancer; 2018 Oct; 17(4):507-515. PubMed ID: 29147930
[TBL] [Abstract][Full Text] [Related]
31. Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers.
van der Post RS; Kiemeney LA; Ligtenberg MJ; Witjes JA; Hulsbergen-van de Kaa CA; Bodmer D; Schaap L; Kets CM; van Krieken JH; Hoogerbrugge N
J Med Genet; 2010 Jul; 47(7):464-70. PubMed ID: 20591884
[TBL] [Abstract][Full Text] [Related]
32. Phenotype comparison of MLH1 and MSH2 mutation carriers in a cohort of 1,914 individuals undergoing clinical genetic testing in the United States.
Kastrinos F; Stoffel EM; Balmaña J; Steyerberg EW; Mercado R; Syngal S
Cancer Epidemiol Biomarkers Prev; 2008 Aug; 17(8):2044-51. PubMed ID: 18708397
[TBL] [Abstract][Full Text] [Related]
33. Association between the Lynch syndrome gene MSH2 and breast cancer susceptibility in a Canadian familial cancer registry.
Goldberg M; Bell K; Aronson M; Semotiuk K; Pond G; Gallinger S; Zbuk K
J Med Genet; 2017 Nov; 54(11):742-746. PubMed ID: 28779004
[TBL] [Abstract][Full Text] [Related]
34. Cancer-risk by family history and mismatch-repair mutation in Lynch syndrome.
Marques-de-Sá I; Castro R; Pita I; Dinis-Ribeiro M; Brandão C
Scand J Gastroenterol; 2020 Jun; 55(6):701-705. PubMed ID: 32448028
[No Abstract] [Full Text] [Related]
35. Evidence for classification of c.1852_1853AA>GC in MLH1 as a neutral variant for Lynch syndrome.
Castillejo A; Guarinos C; Martinez-Canto A; Barbera VM; Egoavil C; Castillejo MI; Perez-Carbonell L; Sanchez-Heras AB; Segura A; Ochoa E; Lazaro R; Ruiz-Ponte C; Bujanda L; Andreu M; Castells A; Carracedo A; Llor X; Clofent J; Alenda C; Paya A; Jover R; Soto JL
BMC Med Genet; 2011 Jan; 12():12. PubMed ID: 21247423
[TBL] [Abstract][Full Text] [Related]
36. Risks of primary extracolonic cancers following colorectal cancer in lynch syndrome.
Win AK; Lindor NM; Young JP; Macrae FA; Young GP; Williamson E; Parry S; Goldblatt J; Lipton L; Winship I; Leggett B; Tucker KM; Giles GG; Buchanan DD; Clendenning M; Rosty C; Arnold J; Levine AJ; Haile RW; Gallinger S; Le Marchand L; Newcomb PA; Hopper JL; Jenkins MA
J Natl Cancer Inst; 2012 Sep; 104(18):1363-72. PubMed ID: 22933731
[TBL] [Abstract][Full Text] [Related]
37. Spectrum of MLH1 and MSH2 mutations in Chilean families with suspected Lynch syndrome.
Alvarez K; Hurtado C; Hevia MA; Wielandt AM; de la Fuente M; Church J; Carvallo P; López-Köstner F
Dis Colon Rectum; 2010 Apr; 53(4):450-9. PubMed ID: 20305446
[TBL] [Abstract][Full Text] [Related]
38. A new mutL homolog 1 c.1896+5G>A germline mutation detected in a Lynch syndrome-associated lung and gastric double primary cancer patient.
Chen X; Li X; Liang H; Wei L; Cui Q; Yao M; Wu X
Mol Genet Genomic Med; 2019 Aug; 7(8):e787. PubMed ID: 31207149
[TBL] [Abstract][Full Text] [Related]
39. Testing strategies to reduce morbidity and mortality from Lynch syndrome.
Keränen A; Ghazi S; Carlson J; Papadogiannakis N; Lagerstedt-Robinson K; Lindblom A
Scand J Gastroenterol; 2018 Dec; 53(12):1535-1540. PubMed ID: 30572730
[TBL] [Abstract][Full Text] [Related]
40. Frequency of rearrangements in Lynch syndrome cases associated with MSH2: characterization of a new deletion involving both EPCAM and the 5' part of MSH2.
Pérez-Cabornero L; Infante Sanz M; Velasco Sampedro E; Lastra Aras E; Acedo Becares A; Miner Pino C; Durán Domínguez M
Cancer Prev Res (Phila); 2011 Oct; 4(10):1556-62. PubMed ID: 21791569
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
